ReviewDiscover nano2026
Nanotechnology revolutionizing antimicrobial therapy for superbug infections.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CRISPR/Cas system as a novel therapeutic strategy to combat multi-drug-resistant bacteria.Archives of microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious diseases still pose one of the leading causes of morbidity and mortality in the world, and the problem of antimicrobial resistance is becoming more and more dangerous to the health of global populations. Multidrug-resistant (MDR) bacteria have emerged rapidly, and this has become a cause of concern among international health organizations and government agencies such as the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). The scarcity of the emergence of new antimicrobial agents and the decreasing efficacy of the current antibiotics predominantly cause this crisis. The mechanisms of bacterial resistance are varied and some of them include enzyme inactivation, low-membrane permeability, target site protection or alteration, target overexpression, structural changes of the enzymes or cellular structures, and increased efflux through overexpressed efflux pumps. Due to their distinctive physicochemical characteristics, nanoparticles have become the potentially promising antimicrobial agents that can either work alone or serve as the carriers of antimicrobial agents without necessarily undergoing the standard mechanisms of resistance. Nanoparticle categories, such as metallic, organic, carbon-based, and hybrid systems have proved to be very effective with regard to antibacterial activity against MDR pathogens. Moreover, nanoparticles are under investigation in combination with plant-derived antimicrobials to improve the ability and minimize the toxicity. Recent methods of using nanoparticles are biofilm disruption, quorum sensing, plasmid eradication, efflux pump, and synergist antimicrobial combinations. Irrespective of these improvements, there are safety, biocompatibility, scalability, and environmental impact issues. This review comprises newly developed developments in nanoparticle-based approaches to addressing drug-resistant bacteria and addresses their clinical translation possibilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.